CardiolRx Pharmaceutical Cannabidiol
In collaboration with Dalton Pharma Services, Cardiol is developing unique manufacturing expertise in the production of pharmaceutical cannabinoids in support of its nanotherapeutics program in heart failure.
With the de-scheduling of cannabinoids from the federal CDSA expected to occur on October 17, 2018, Cardiol believes there is a significant opportunity to exploit this manufacturing expertise to commercialize pharmaceutical cannabinoid products.
• FDA/Health Canada certified cGMP manufacturer
• Pharmaceutical cannabidiol
• Precise dosing
• Non-THC-containing product
• >99.5% purity
New Frontier Data estimates that annual sales in Canada of medical cannabinoids in 2017 exceeded $600 million and forecasts sales to reach $1.2 billion in 2018. Cardiol believes that a pharmaceutical cannabinoid product, manufactured by a Health Canada regulated/FDA registered cGMP facility, will have key competitive advantages regarding traceability, dosimetry, consistency, and purity. Cardiol also believes this new class of cannabinoid-based products will provide the Company with a significant near-term revenue opportunity.